PL3328864T3 - Związki i kompozycje terapeutyczne do leczenia zaburzeń społecznych i zaburzeń związanych z używaniem substancji psychoaktywnych - Google Patents

Związki i kompozycje terapeutyczne do leczenia zaburzeń społecznych i zaburzeń związanych z używaniem substancji psychoaktywnych

Info

Publication number
PL3328864T3
PL3328864T3 PL16820570.6T PL16820570T PL3328864T3 PL 3328864 T3 PL3328864 T3 PL 3328864T3 PL 16820570 T PL16820570 T PL 16820570T PL 3328864 T3 PL3328864 T3 PL 3328864T3
Authority
PL
Poland
Prior art keywords
disorders
compositions
therapeutic compounds
substance use
treating social
Prior art date
Application number
PL16820570.6T
Other languages
English (en)
Inventor
Iain Stewart Mcgregor
Michael Kassiou
Michael Thomas Bowen
Callum HICKS
William Jorgensen
Original Assignee
Kinoxis Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015902659A external-priority patent/AU2015902659A0/en
Application filed by Kinoxis Therapeutics Pty Ltd filed Critical Kinoxis Therapeutics Pty Ltd
Publication of PL3328864T3 publication Critical patent/PL3328864T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL16820570.6T 2015-07-06 2016-07-06 Związki i kompozycje terapeutyczne do leczenia zaburzeń społecznych i zaburzeń związanych z używaniem substancji psychoaktywnych PL3328864T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015902659A AU2015902659A0 (en) 2015-07-06 Therapeutic compounds and compositions for treating social disorders and substance use disorders
PCT/AU2016/050588 WO2017004674A1 (en) 2015-07-06 2016-07-06 Therapeutic compounds and compositions for treating social disorders and substance use disorders

Publications (1)

Publication Number Publication Date
PL3328864T3 true PL3328864T3 (pl) 2023-02-27

Family

ID=57684596

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16820570.6T PL3328864T3 (pl) 2015-07-06 2016-07-06 Związki i kompozycje terapeutyczne do leczenia zaburzeń społecznych i zaburzeń związanych z używaniem substancji psychoaktywnych

Country Status (16)

Country Link
US (4) US11033555B2 (pl)
EP (1) EP3328864B1 (pl)
JP (2) JP7089825B2 (pl)
KR (1) KR102686349B1 (pl)
CN (1) CN107922420B (pl)
AU (1) AU2016289271B2 (pl)
DK (1) DK3328864T3 (pl)
ES (1) ES2932194T3 (pl)
HU (1) HUE060496T2 (pl)
IL (1) IL256684B (pl)
MX (1) MX389545B (pl)
PL (1) PL3328864T3 (pl)
PT (1) PT3328864T (pl)
RU (1) RU2715384C2 (pl)
SI (1) SI3328864T1 (pl)
WO (1) WO2017004674A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3328864T3 (pl) 2015-07-06 2023-02-27 Kinoxis Therapeutics Pty Ltd Związki i kompozycje terapeutyczne do leczenia zaburzeń społecznych i zaburzeń związanych z używaniem substancji psychoaktywnych
CA3046809A1 (en) * 2016-12-12 2018-06-21 The University Of Sydney Non-peptide oxytocin receptor agonists
US20220079953A1 (en) * 2018-11-23 2022-03-17 The University Of Sydney Methods for management of weight
KR20220063198A (ko) * 2019-09-06 2022-05-17 키녹시스 테라퓨틱스 피티와이 리미티드 아편유사제 금단의 치료
US20240287074A1 (en) * 2020-09-07 2024-08-29 Kinoxis Therapeutics Pty Ltd Salts and crystals
JP2023552485A (ja) * 2020-12-14 2023-12-15 キノシス・セラピューティクス・ピーティーワイ・リミテッド オキシトシン受容体モジュレーター
AU2022240104A1 (en) * 2021-03-18 2023-10-05 Kinoxis Therapeutics Pty Ltd Methods of treatment
CN115677585B (zh) * 2022-10-31 2024-03-19 上海群力化工有限公司 一种甲醛吡唑衍生物的合成工艺
EP4617260A1 (en) 2022-11-09 2025-09-17 Mitsubishi Gas Chemical Next Company, Inc. Production method for 1-alkyl-5-hydroxypyrazole
WO2025172368A1 (en) 2024-02-13 2025-08-21 Syngenta Crop Protection Ag (5-isoxazol-3-yl)-[4-(pyrazol-4-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone derivatives for use as fungicides
WO2025191053A1 (en) 2024-03-14 2025-09-18 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2025210095A1 (en) 2024-04-03 2025-10-09 Syngenta Crop Protection Ag Microbiocidal tetrahydroisoquinoline compounds
WO2026022173A1 (en) 2024-07-26 2026-01-29 Syngenta Crop Protection Ag Microbiocidal pyrazole compounds
CN119386023A (zh) * 2024-10-25 2025-02-07 南方医科大学南方医院 地尔硫卓在制备治疗自闭症的药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115515D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Oxytocin agonisys
EP1512687A1 (en) * 2003-09-05 2005-03-09 Ferring B.V. Piperazines as oxytocin agonists
EP1632494A1 (en) * 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
AU2006306547A1 (en) 2005-10-24 2007-05-03 Wyeth Tricyclic compounds useful as oxytocin receptor agonists
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
EP2571360A4 (en) 2010-05-19 2013-07-31 Univ North Carolina METHOD AND FORMULATIONS FOR OXYTOCIN TREATMENT OF DRUG ABUSE AND PSYCHIATRIC AND OTHER DISORDERS
GB201015371D0 (en) 2010-09-14 2010-10-27 Optinose As Nasal delivery
KR20140124465A (ko) 2013-04-17 2014-10-27 인제대학교 산학협력단 사회 정서 관련 행동 조절을 위한 비강용 옥시토신의 용도
PL3328864T3 (pl) * 2015-07-06 2023-02-27 Kinoxis Therapeutics Pty Ltd Związki i kompozycje terapeutyczne do leczenia zaburzeń społecznych i zaburzeń związanych z używaniem substancji psychoaktywnych
KR20220063198A (ko) 2019-09-06 2022-05-17 키녹시스 테라퓨틱스 피티와이 리미티드 아편유사제 금단의 치료
AU2022240104A1 (en) 2021-03-18 2023-10-05 Kinoxis Therapeutics Pty Ltd Methods of treatment

Also Published As

Publication number Publication date
US20190290658A1 (en) 2019-09-26
RU2018103873A (ru) 2019-08-06
DK3328864T3 (da) 2022-12-05
KR20180023992A (ko) 2018-03-07
HK1252813A1 (zh) 2019-06-06
IL256684A (en) 2018-03-29
JP2018525351A (ja) 2018-09-06
RU2715384C2 (ru) 2020-02-27
CA2991236A1 (en) 2017-01-12
NZ738672A (en) 2022-11-25
JP7089825B2 (ja) 2022-06-23
US11890287B2 (en) 2024-02-06
IL256684B (en) 2022-06-01
PT3328864T (pt) 2022-12-07
CN107922420A (zh) 2018-04-17
RU2018103873A3 (pl) 2019-09-04
MX2017017171A (es) 2018-04-30
EP3328864B1 (en) 2022-09-07
EP3328864A1 (en) 2018-06-06
US11033555B2 (en) 2021-06-15
AU2016289271B2 (en) 2020-12-03
CN107922420B (zh) 2021-12-31
US20240245706A1 (en) 2024-07-25
US12458648B2 (en) 2025-11-04
US20220362261A1 (en) 2022-11-17
AU2016289271A1 (en) 2018-01-25
JP2022130418A (ja) 2022-09-06
BR112018000059A2 (pt) 2018-09-04
JP7490018B2 (ja) 2024-05-24
SI3328864T1 (sl) 2023-02-28
US20260034142A1 (en) 2026-02-05
EP3328864A4 (en) 2019-01-09
ES2932194T3 (es) 2023-01-16
MX389545B (es) 2025-03-20
WO2017004674A1 (en) 2017-01-12
HUE060496T2 (hu) 2023-03-28
KR102686349B1 (ko) 2024-07-17

Similar Documents

Publication Publication Date Title
IL256684B (en) Medicinal compounds and preparations for the treatment of social disorders and substance use disorders
IL256166B (en) Compounds for use in treating neuromuscular disorders
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
IL251066B (en) Preparations and methods for the treatment of metabolic disorders
ZA201700311B (en) Compositions and methods of use for treating metabolic disorders
SG11201705093UA (en) Composition for treating il-6-related diseases
SG10202013034QA (en) Compositions, devices, and methods for the treatment of alcohol use disorder
SI3261726T1 (sl) Sestavek za zdravljenje aken
IL258032B (en) Compounds and preparations for the treatment of ocular disorders
IL254842A0 (en) Therapeutic preparations and methods for use in cancer treatment
ZA201807653B (en) New tetrahydropyrimidodiazepin and dihydropyridodiazepin compounds for treating pain and pain related conditions
IL251616A0 (en) Methods and compounds for the treatment and prevention of muscle loss
GB201612043D0 (en) Composition for treatment of disorders
PL3373922T3 (pl) Kompozycje i sposoby do stosowania do leczenia homocystynurii
SG11201705524SA (en) Compositions and methods for the treatment of inflammation and pain
IL251736B (en) Methods and compositions for the treatment of radiation-related disorders
IL249440B (en) Pharmaceutical compounds and preparations containing them for the treatment of neurodegenerative diseases
SG11201802292UA (en) Composition for treating pain
PL3377089T3 (pl) Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowego
GB201513543D0 (en) Compositions for use in the treatment of diabetes
PL3164110T3 (pl) Kompozycje farmaceutyczne do leczenia łuszczycy
AU2015902659A0 (en) Therapeutic compounds and compositions for treating social disorders and substance use disorders
SG10201400823PA (en) Therapeutic methods and compositions for treating diabetes
SG10201400824YA (en) Therapeutic Methods And Compositions For Treating Diabetes Utilizing Diterpenoid Compounds
PT3524255T (pt) Composição para o tratamento do acne